

Claim Amendment

Claims 1-53 (canceled)

Claim 54 (currently amended): A method of inhibiting binding of an anti-double stranded (ds)-DNA antibody to glomeruli of renal tissue in a subject, wherein the anti-ds-DNA antibody binds to the same epitope as an R4A antibody, the method comprising administering to said subject at least one peptide in an amount effective to bind to an anti-ds-DNA antibody in the subject, wherein said peptide comprises a D-amino acid sequence of X1-Trp-X1-Tyr-X2, wherein X1 represents Asp or Glu, and X2 represents Gly or Ser.

Claim 55 (previously presented): The method according to Claim 54 wherein said peptide is 5-30 D-amino acids in length.

Claim 56 (previously presented): The method according to Claim 54 wherein said peptide is 5-15 D-amino acids in length.

Claim 57 (previously presented): The method according to Claim 54 wherein said peptide is 5-10 D-amino acids in length.

Claim 58 (previously presented): The method according to Claim 54 wherein said peptide is 5 D-amino acids in length.

Claims 59-70 (canceled)

Claim 71 (previously presented): The method according to Claim 54 wherein said peptide is 5-30 amino acids in length and comprises d-Asp-Trp-Glu-Tyr-Ser.

Claim 72 (previously presented): The method according to Claim 71 wherein said peptide is 5-15 amino acids in length.

Claim 73 (previously presented): The method according to Claim 71 wherein said peptide is 5-10 amino acids in length.

Claim 74 (previously presented): The method according to Claim 71 wherein said peptide consists of d-Asp-Trp-Glu-Tyr-Ser.

Claim 75 (previously presented): The method of claim 54, wherein the subject has glomerulonephritis.